A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo

Paul N. Reynolds, Kurt R. Zinn, Vitaliy D. Gavrilyuk, Irina V. Balyasnikova, Buck E. Rogers, Donald J. Buchsbaum, Ming H. Wang, David J. Miletich, William E. Grizzle, Joanne T. Douglas, Sergei M. Danilov, David T. Curiel*

*Corresponding author for this work

Research output: Contribution to journalArticle

187 Scopus citations

Abstract

Adenoviral (Ad) vectors are promising gene therapy vehicles due to their in vivo stability and efficiency, but their potential utility is compromised by their restricted tropism. Targeting strategies have been devised to improve the efficacy of these agents, but specific targeting following in vivo systemic administration of vector has not previously been demonstrated. The distinct aim of the current study was to determine whether an Ad-targeting strategy could maintain fidelity upon systemic vascular administration. We used a bispecific antibody to target Ad infection specifically to angiotensin-converting enzyme (ACE), which is preferentially expressed on pulmonary capillary endothelium and which may thus enable gene therapy for pulmonary vascular disease. Cell-specific gene delivery to ACE-expressing cells was first confirmed in vitro. Administration of retargeted vector complex via tail vein injection into rats resulted in at least a 20-fold increase in both Ad DNA localization and luciferase transgene expression in the lungs, compared to the untargeted vector. Furthermore, targeting led to reduced transgene expression in nontarget organs, especially the liver, where the reduction was over 80%. Immunohistochemical and immunoelectron microscopy analysis confirmed that the pulmonary transgene expression was specifically localized to endothelial cells. Enhancement of transgene expression in the lungs as a result of the ACE-targeting strategy was also confirmed using a new noninvasive imaging technique. This study shows that a retargeting approach can indeed specifically modify the gene delivery properties of an Ad vector given systemically and thus has encouraging implications for the further development of targetable, injectable Ad vectors.

Original languageEnglish (US)
Pages (from-to)562-578
Number of pages17
JournalMolecular Therapy
Volume2
Issue number6
DOIs
StatePublished - Jan 1 2000

Keywords

  • Adenovirus
  • Angiotensin-converting enzyme
  • Gene therapy
  • Lung
  • Noninvasive imaging
  • Targeting
  • Tropism
  • Vascular

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo'. Together they form a unique fingerprint.

  • Cite this

    Reynolds, P. N., Zinn, K. R., Gavrilyuk, V. D., Balyasnikova, I. V., Rogers, B. E., Buchsbaum, D. J., Wang, M. H., Miletich, D. J., Grizzle, W. E., Douglas, J. T., Danilov, S. M., & Curiel, D. T. (2000). A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Molecular Therapy, 2(6), 562-578. https://doi.org/10.1006/mthe.2000.0205